Fundraising Fox

Sonavex

Baltimore, US · Founded 2013 · Delaware corporation · 7 known investors

sonavex.com ↗

Sonavex develops medical device technologies focused on vascular access and related clinical applications, drawing on ultrasound-based imaging and monitoring products. The company serves clinical and surgical care settings, particularly in the dialysis and renal care space.

BiotechDigital HealthHealthtechMedical Devicesin /sonavex@Sonavex

Founders & leadership

DN
David NarrowExecutive Officer, Director
JP
Jerry PrinceDirector
DO
Devin O'Brien-CoonCo-Founder & Chairman
JR
John RappeExecutive Officer
AY
Alex YevzlinExecutive Officer
EP
Evan PritchardDirector
JL
Jerry L. PrinceCo-Founder
RH
Robert HallenbeckDirector
MJ
Michael J. Hennessy, Jr.Director
BN
Bill NilandDirector

Investors · 7

FusionPalo Alto · $500K – $1M
JStar Capital InvestmentsAustin
Keiretsu ForumSan Francisco · $250K – $2M
Maryland TEDCOUpper Marlboro · $500K – $1.5M
Rembrandt Venture PartnersLaramie
Riptide VenturesBaltimore · $750Kvia Mike Leffer · inferred
TMC Venture FundHouston

Reported raises · per SEC filings

Form D private placements
▶$3.1MraisedJul 2026 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David NarrowExecutive Officer, Director
  • Devin O'Brien-CoonDirector
  • Alex YevzlinExecutive Officer
  • William NilandDirector
  • Robert HallenbeckDirector
  • Evan PritchardDirector
  • Michael J. Hennessy, Jr.Director
Offering amount
$15M
Amount sold
$3.1M
Proceeds to insiders
$400K
First sale
Jul 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$15MraisedNov 2024 · 45 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Bill NilandDirector
  • John RappeExecutive Officer
  • David NarrowExecutive Officer, Director
  • Jerry PrinceDirector
  • Robert HallenbeckDirector
  • Devin O'Brien-CoonExecutive Officer, Director
  • Michael J. Hennessy, Jr.Director
Offering amount
$15M
Amount sold
$15M
Proceeds to insiders
$300K
First sale
Aug 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.8MraisedNov 2019 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David NarrowExecutive Officer, Director
  • Devin O'Brien-CoonExecutive Officer, Director
  • Bill NilandDirector
  • Jerry PrinceDirector
  • Robert HallenbeckDirector
Amount sold
$1.8M
First sale
Oct 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.2MraisedJan 2017 · 12 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Bill NilandDirector
  • David NarrowExecutive Officer, Director
  • Devin O'Brien-CoonExecutive Officer, Director
  • Jerry L. PrinceDirector
  • Robert HallenbeckDirector
Offering amount
$4.3M
Amount sold
$2.2M
Proceeds to insiders
$136K
First sale
Aug 2016
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$320.2KraisedOct 2015 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David NarrowExecutive Officer, Director
  • Devin O'Brien-CoonExecutive Officer, Director
  • Jerry PrinceDirector
Offering amount
$320.2K
Amount sold
$320.2K
First sale
Oct 2015
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$70KraisedJun 2015 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David NarrowExecutive Officer
  • Devin O'Brien-CoonExecutive Officer, Director
Offering amount
$400K
Amount sold
$70K
Minimum investment
$5K
First sale
May 2015
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.